Linda Rubinstein

Linda M.
Rubinstein is Chief Financial & Accounting Officer at Nektar Therapeutics since 2026.
Ms. Rubinstein is Partner at FLG Partners LLC since 2010.
Former roles include Chief Financial & Accounting Officer at Adverum Biotechnologies, Inc. from 2022 to 2025, Chief Accounting Officer at Alector, Inc. from 2022 to 2022, Chief Financial Officer at Apexigen, Inc. from 2018 to 2022, Independent Director at Biocept, Inc. from 2021 to 2023, Chief Financial & Accounting Officer at Five Prime Therapeutics, Inc. in 2018, Chief Financial Officer at ArmaGen, Inc. from 2015 to 2020, Chief Financial Officer & Executive Vice President at Emergent Travel Health, Inc. in 2014, Director at Sensor Innovations, Inc. from 2007 to 2015, Chief Financial Officer at Solexa, Inc. from 2005 to 2007, Chief Financial Officer & Senior Vice President at Ingenuity Systems, Inc., Chief Financial Officer at RenovoRx, Inc., Chief Financial Officer at iPierian, Inc., Senior Banker at Lehman Brothers, Inc., Principal at Merrill Lynch Capital Partners, Inc., and Independent Director at Biocept, Inc. Education includes undergraduate and graduate degrees from the University of California, Los Angeles.